Scynexis gains as FDA grants priority review for vaginal infection drug

Scynexis

01/08/2022 16:29

** Shares of Scynexis Inc  SCYX.O  rise 2.6% to $2.37
    ** SCYX says the U.S. FDA accepted and granted priority
review to the market application to expand the label of its oral
drug Brexafemme  urn:newsml:reuters.com:*:nGNX6Z5hMy
    ** FDA to take a decision on approval of the drug for the
prevention of recurrent vulvovaginal candidiasis or vaginal
yeast infection by Nov. 30
    ** Brexafemme had received approval from the U.S. regulator
for the treatment of vaginal yeast infection last year
    ** Stock down 61% YTD including session gains

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))